Sheryl Crow named Hologic's national celebrity spokesperson for breast cancer educational campaign

Hologic, a developer, manufacturer and supplier of diagnostic products, medical imaging systems and surgical products, has announced a partnership with nine-time Grammy award-winning singer, songwriter and breast cancer survivor Sheryl Crow.

Crow will serve as national spokesperson to educate women about accurate mammograms.

"Early detection saves lives—it's that simple," said Crow. "Women need to be advocates for their health, and that means getting annual mammograms starting at age 40 and taking advantage of the best, and most accurate, technologies available. I opted for a Genius exam because early detection is what saved my life—it's a woman's best chance at survival, and it's a chance we all deserve."

Crow will become an integral part of the campaign by educating women through various media efforts, including a satellite media tour and social media outreach and will continue through October, which is Breast Cancer Awareness Month.

"It's an honor to join forces with such a well-known artist and breast cancer survivor days before National Cancer Survivors Day," said Pete Valenti, Hologic's Division President, Breast and Skeletal Health Solutions. "We remain resolute in our commitment to developing innovative new technologies, like the Genius exam, which detects more invasive cancers than conventional mammography, improving a woman's chance of survival. We look forward to working with Sheryl as we continue to spread the message that early detection saves lives."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.